You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

429 Results
Drug
Other Name(s): Xgeva®; Wyost™; Osenvelt™
Updated
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Updated
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Updated
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Updated
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Updated
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Updated
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Adjuvant, Curative
Updated
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours
Intent: Palliative
Funding:
Exceptional Access Program
    ripretinib - For adult patients with advanced gastrointestinal stromal tumours (GIST) who have progression on or intolerance to imatinib, sunitinib and regorafenib
Updated
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - MSI-H/dMMR Locally Advanced Unresectable or Metastatic Colorectal Cancer
New Drug Funding Program
    Nivolumab plus Ipilimumab - MSI-H/dMMR Locally Advanced Unresectable or Metastatic Colorectal Cancer
Updated
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - MSI-H/dMMR Locally Advanced Unresectable or Metastatic Colorectal Cancer
Updated
Dec 2025
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    anastrozole
New
Dec 2025
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    letrozole
New
Dec 2025

Pages